Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

BACKGROUND: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are new oral antidiabetic drugs that reduce hyperglycemia by promoting urinary glucose excretion. Glycosuria produced by SGLT2 inhibitors is associated with weight loss, mainly due to reduced fat volume. We investigated the effects of em...

Descripción completa

Detalles Bibliográficos
Autores principales: Jojima, Teruo, Tomotsune, Takanori, Iijima, Toshie, Akimoto, Kazumi, Suzuki, Kunihiro, Aso, Yoshimasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960737/
https://www.ncbi.nlm.nih.gov/pubmed/27462372
http://dx.doi.org/10.1186/s13098-016-0169-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960737/
https://www.ncbi.nlm.nih.gov/pubmed/27462372
http://dx.doi.org/10.1186/s13098-016-0169-x

Ejemplares similares